Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABEO

Abeona Therapeutics Inc.

Healthcare | Biotechnology
$5.65 -0.02 (-0.35%) as of 2026-07-15 03:06 UTC
Market Cap$310M
Volume1.56M
EPS (TTM)$1.01

Abeona Therapeutics Inc. (NASDAQ: ABEO) is a $310M biotechnology company trading at $5.65 (−0.4% today) — 5.6× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 03:06 UTC.

52-Week Range
Low $4.00High $7.54

What Abeona Therapeutics Inc. does

Abeona Therapeutics is a biopharmaceutical company that develops cell and gene therapies for rare genetic diseases. The FDA approved ZEVASKYN, an autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious genetic skin disease caused by a defect in the COL7A1 gene. ZEVASKYN is manufactured at the company's facility in Cleveland, Ohio and administered through a network of qualified treatment centers.

Summarized from Abeona Therapeutics Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$5.65
Change (1D)-0.02 (-0.35%)
Market cap$310M
Volume1.56M shares
52-week range$4.00 – $7.54
Valuation
P/E (TTM)5.59×
EPS (TTM)$1.01
Price/book1.95×
Return on equity44.71%
Debt/equity0.13
Returns
52-week return+41.3%
Revenue, margins & earnings
FY2021: net loss $85M on revenue $3M$3MFY2021FY2022: net loss $40M on revenue $1M$1MFY2022FY2023: net loss $54M on revenue $4M$4MFY2023FY2025 Revenue: $6M — margin split not shown (non-operating gains)FY2025: net income $71M exceeded revenue $6M by $65M — non-operating gains (e.g. asset sales), not operating profit$6MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-09
  • 2026-07-09Vasanthavada MadhavChief Commercial OfficerSELL-12,606$87.8K
  • 2026-07-09Vazzano Joseph WalterChief Financial OfficerSELL-24,880$173.3K
  • 2026-07-09Seshadri VishwasChief Executive OfficerSELL-67,971$473.3K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • Nantahala Capital Management, LLC5,013,052$22.46M+1.0%
  • ADAGE CAPITAL PARTNERS GP, L.L.C.3,047,985$16.09M-0.8%
  • VANGUARD GROUP INC2,757,143$14.53M+5.9%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Abeona Therapeutics Inc. do?

Abeona Therapeutics is a biopharmaceutical company that develops cell and gene therapies for rare genetic diseases.

What is ABEO's valuation?

ABEO trades at $5.65, 5.59× trailing earnings, as of 2026-07-15.

When did ABEO last file with the SEC?

Abeona Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 03:06 UTC. This page is also available as JSON at /api/data?ticker=ABEO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABEO and 3,500+ tickers.

Create a free account — keep ABEO
For your agent
GET /api/data?ticker=ABEO

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt